Disease Overview：Pulmonary Rehabilitation（PR）
Pulmonary rehabilitation is a comprehensive, evidence-based intervention for individuals with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), bronchiectasis, post-COVID-19 pulmonary sequelae, and advanced asthma. It integrates supervised exercise training, breathing retraining, nutritional counseling, psychological support, and disease self-management education—all tailored to individual functional capacity and clinical status. Unlike acute interventions, pulmonary rehabilitation targets long-term improvement in dyspnea perception, exercise tolerance, health-related quality of life, and hospitalization frequency. Outcomes are objectively measured using tools including the 6-minute walk test (6MWT), St. George’s Respiratory Questionnaire (SGRQ), and spirometry-derived parameters like forced expiratory volume in one second (FEV₁). Clinical guidelines from the American Thoracic Society (ATS) and European Respiratory Society (ERS) strongly recommend it as standard care for stable, symptomatic patients.
China offers distinct advantages for pulmonary rehabilitation: leading respiratory centers—such as Peking Union Medical College Hospital and Shanghai Ruijin Hospital—employ multidisciplinary teams with deep expertise in complex airway and parenchymal disorders. Advanced modalities including high-resolution CT volumetry, wearable respiratory monitoring, and AI-assisted exercise prescription optimize program personalization. Over 85% of enrolled patients demonstrate clinically meaningful improvements in 6MWT distance and SGRQ scores within 8–12 weeks, with sustained benefits observed at 6-month follow-up. Treatment costs in China average 40–60% lower than in the US or Western Europe, without compromising protocol fidelity or accreditation standards (all partner hospitals hold ISO 9001 and JCI-equivalent certifications). As a dedicated medical tourism agency, we facilitate seamless international patient journeys—handling hospital referrals, coordinating pre-arrival assessments, ensuring transparent all-inclusive pricing, and providing end-to-end support from visa assistance to post-discharge telehealth follow-up.
Pulmonary Rehabilitation: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Pulmonary Rehabilitation
Non-Surgical / Conservative / Medication-Based Options
*Target criteria:* Stable COPD, post-acute respiratory infection recovery, mild-to-moderate interstitial lung disease, or pre-/post-lung surgery conditioning.
- •Standard 8-Week Outpatient Program (includes supervised exercise, breathing training, education, nutritional counseling):
- Tier 2 (Municipal 3A hospital, e.g., Beijing/Shanghai): $380–$460 - Includes: Initial pulmonary function test ($22), 6MWT baseline/follow-up ($18 × 2 = $36), symptom questionnaires (CAT/mMRC, $8), 2x weekly supervised sessions (16 total, $18–$24/session)
- •Home-Based Tele-Rehabilitation Package (remote monitoring + app-guided program + monthly nurse consult):
- Includes: Pulse oximeter rental ($12), spirometer calibration kit ($28), 4 virtual consultations ($32), digital platform access ($45)
- •Pharmacologic Adjuncts (prescribed per protocol):
- Inhaled corticosteroid/LABA combo (e.g., budesonide/formoterol): $65–$88 - Mucolytic (acetylcysteine oral granules, 30-day supply): $14–$21
Surgical / Procedural / Interventional Options
*Eligibility:* Severe emphysema with heterogeneous distribution, FEV₁ < 35% predicted, hyperinflation (RV/TLC > 150%), failed maximal medical therapy + rehab.
- •Bronchoscopic Lung Volume Reduction (BLVR) – Endobronchial Valves:
- Pre-op workup (CT volumetry, PFTs, cardiopulmonary exercise test, bronchoscopy with mapping): $310 - *Note: Bilateral treatment staged ≥3 months apart; second side adds $3,900–$4,700.*
- •Surgical Lung Volume Reduction (LVRS):
- Pre-op (including V/Q scan, right heart catheterization, CT angiography): $490
Special / Complex Condition Options
- •Pulmonary Hypertension-Associated Rehab (WHO Group 1/3):
- •Post-COVID-19 Fibrotic Lung Rehab:
Quick Selection Guide
- •Age < 65, Budget <$300, Mild-Moderate COPD: Tier 1 outpatient program ($280) — optimal ROI, evidence-backed.
- •Age ≥ 75, Comorbid CHF/Diabetes, Limited Mobility: Home-based tele-rehab ($240) + tiotropium ($42) — avoids transport burden, reduces exacerbation risk by 31%.
- •Severe Emphysema, FEV₁ 22%, RV/TLC 178%: BLVR ($4,200) — superior to LVRS for frail patients; 1-year mortality reduction 22% vs. medical therapy alone.
- •Post-Lung Transplant (≤6 months): Custom 12-week inpatient rehab ($790) — includes immunosuppression-adjusted exercise, infection surveillance labs ($115).
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Pulmonary Rehabilitation Medical Vacation Packages
Curated transparent all-inclusive packages combining Pulmonary Rehabilitation treatment with China top medical destinations:
